Teligent Inc (TLGT)

0.1735  -0.03 (-13.85%)

After market: 0.1717 0 (-1.04%)

Fundamental Rating

2

TLGT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of TLGT have multiple concerns. TLGT does not seem to be growing, but still is valued expensively.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

TLGT had negative earnings in the past year.

1.2 Ratios

Industry RankSector Rank
ROA -101.27%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM -296.25%
PM (TTM) -197.78%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

3

2. Health

2.1 Basic Checks

There is no outstanding debt for TLGT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -6.66, we must say that TLGT is in the distress zone and has some risk of bankruptcy.
TLGT has a Debt/Equity ratio of -2.67. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity -2.67
Debt/FCF N/A
Altman-Z -6.66
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 4.10 indicates that TLGT has no problem at all paying its short term obligations.
A Quick Ratio of 2.74 indicates that TLGT has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 4.1
Quick Ratio 2.74

More info and screens

2

3. Growth

3.1 Past

TLGT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 27.02%, which is quite impressive.
The Revenue for TLGT has decreased by -16.53% in the past year. This is quite bad
The Revenue has been growing slightly by 0.47% on average over the past years.
EPS 1Y (TTM)27.02%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q90.91%
Revenue 1Y (TTM)-16.53%
Revenue growth 3Y-9.04%
Revenue growth 5Y0.47%
Revenue growth Q2Q-23.21%

3.2 Future

The Earnings Per Share is expected to grow by 17.63% on average over the next years. This is quite good.
The Revenue is expected to decrease by -0.27% on average over the next years.
EPS Next Y131.61%
EPS Next 2Y65.35%
EPS Next 3Y24.17%
EPS Next 5Y17.63%
Revenue Next Year-16.85%
Revenue Next 2Y-16.02%
Revenue Next 3Y-0.47%
Revenue Next 5Y-0.27%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

TLGT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 0.04, the valuation of TLGT can be described as very cheap.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.35, TLGT is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 0.04

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -0.85

4.3 Compensation for Growth

TLGT's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as TLGT's earnings are expected to grow with 24.17% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y65.35%
EPS Next 3Y24.17%

More info and screens

0

5. Dividend

5.1 Amount

TLGT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Teligent Inc

NASDAQ:TLGT (10/15/2021, 7:08:54 PM)

After market: 0.1717 0 (-1.04%)

0.1735

-0.03 (-13.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap16.10M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 0.04
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -101.27%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM -296.25%
PM (TTM) -197.78%
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity -2.67
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 4.1
Quick Ratio 2.74
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)27.02%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y131.61%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-16.53%
Revenue growth 3Y-9.04%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y